128 related articles for article (PubMed ID: 19569219)
1. Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Humphreys JE; Lou Y; Lee EJ
J Pharm Sci; 2010 Feb; 99(2):1046-62. PubMed ID: 19569219
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
Yamasaki Y; Ieiri I; Kusuhara H; Sasaki T; Kimura M; Tabuchi H; Ando Y; Irie S; Ware J; Nakai Y; Higuchi S; Sugiyama Y
Clin Pharmacol Ther; 2008 Jul; 84(1):95-103. PubMed ID: 18167504
[TBL] [Abstract][Full Text] [Related]
3. The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects.
Adkison KK; Vaidya SS; Lee DY; Koo SH; Li L; Mehta AA; Gross AS; Polli JW; Lou Y; Lee EJ
Br J Clin Pharmacol; 2008 Aug; 66(2):233-9. PubMed ID: 18429968
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe.
Urquhart BL; Ware JA; Tirona RG; Ho RH; Leake BF; Schwarz UI; Zaher H; Palandra J; Gregor JC; Dresser GK; Kim RB
Pharmacogenet Genomics; 2008 May; 18(5):439-48. PubMed ID: 18408567
[TBL] [Abstract][Full Text] [Related]
5. Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.
Tanaka Y; Kitamura Y; Maeda K; Sugiyama Y
J Pharm Sci; 2015 Sep; 104(9):3039-48. PubMed ID: 25639366
[TBL] [Abstract][Full Text] [Related]
6. No effects of pantoprazole on the pharmacokinetics of rosuvastatin in healthy subjects.
Huguet J; Lu J; Gaudette F; Chiasson JL; Hamet P; Michaud V; Turgeon J
Eur J Clin Pharmacol; 2016 Aug; 72(8):925-31. PubMed ID: 27146814
[TBL] [Abstract][Full Text] [Related]
7. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
Dahan A; Amidon GL
Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
[TBL] [Abstract][Full Text] [Related]
8. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Zhang W; Yu BN; He YJ; Fan L; Li Q; Liu ZQ; Wang A; Liu YL; Tan ZR; Fen-Jiang ; Huang YF; Zhou HH
Clin Chim Acta; 2006 Nov; 373(1-2):99-103. PubMed ID: 16784736
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design.
Lee CA; O'Connor MA; Ritchie TK; Galetin A; Cook JA; Ragueneau-Majlessi I; Ellens H; Feng B; Taub ME; Paine MF; Polli JW; Ware JA; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2015 Apr; 43(4):490-509. PubMed ID: 25587128
[TBL] [Abstract][Full Text] [Related]
10. Deletion of Abcg2 has differential effects on excretion and pharmacokinetics of probe substrates in rats.
Huang L; Be X; Tchaparian EH; Colletti AE; Roberts J; Langley M; Ling Y; Wong BK; Jin L
J Pharmacol Exp Ther; 2012 Nov; 343(2):316-24. PubMed ID: 22869929
[TBL] [Abstract][Full Text] [Related]
11. Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines.
Gotanda K; Hirota T; Saito J; Fukae M; Egashira Y; Izumi N; Deguchi M; Kimura M; Matsuki S; Irie S; Ieiri I
Sci Rep; 2016 Aug; 6():32299. PubMed ID: 27571936
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
Zaher H; Khan AA; Palandra J; Brayman TG; Yu L; Ware JA
Mol Pharm; 2006; 3(1):55-61. PubMed ID: 16686369
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.
Karibe T; Hagihara-Nakagomi R; Abe K; Imaoka T; Mikkaichi T; Yasuda S; Hirouchi M; Watanabe N; Okudaira N; Izumi T
Pharm Res; 2015 May; 32(5):1634-47. PubMed ID: 25380981
[TBL] [Abstract][Full Text] [Related]
14. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
[TBL] [Abstract][Full Text] [Related]
15. Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene.
Gotanda K; Tokumoto T; Hirota T; Fukae M; Ieiri I
Br J Clin Pharmacol; 2015 Nov; 80(5):1236-7. PubMed ID: 25872459
[No Abstract] [Full Text] [Related]
16. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
[TBL] [Abstract][Full Text] [Related]
17. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
[TBL] [Abstract][Full Text] [Related]
18. Curcumin as an In Vivo Selective Intestinal Breast Cancer Resistance Protein Inhibitor in Cynomolgus Monkeys.
Karibe T; Imaoka T; Abe K; Ando O
Drug Metab Dispos; 2018 May; 46(5):667-679. PubMed ID: 29358184
[TBL] [Abstract][Full Text] [Related]
19. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
Wiese MD; Alotaibi N; O'Doherty C; Sorich MJ; Suppiah V; Cleland LG; Proudman SM
Pharmacogenomics J; 2014 Aug; 14(4):350-5. PubMed ID: 24394199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
